Lipigon’s patent strategy aims to establish strong protection for the company’s current and future products under development, as well as their medical applications.

An international patent application covering a large number of substances identified as potential ANGPTL4 inhibitors was filed in November 2019, as a result of a collaboration with Secarna. This application has since been pursued in several countries and is now primarily focused on Lipisense® and its medical use.

In October 2023, Lipigon was granted a patent by the United States Patent and Trademark Office (USPTO) for Lipisense®, specifically regarding its use in the treatment of cardiometabolic diseases (cardiovascular diseases and metabolic conditions such as type 2 diabetes). A corresponding patent for Lipisense® has also been granted by the Japan Patent Office.

The European patent application is still under examination.

LIPISENSE® is a registered trademark approved in Sweden, the EU, the United Kingdom, the United States, Australia, and Canada.

Patent Application Number: 
PCT/EP2019/081161 published as WO 2020/099478.